<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Semaglutide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Semaglutide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Semaglutide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="116157" href="/d/html/116157.html" rel="external">see "Semaglutide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="140434" href="/d/html/140434.html" rel="external">see "Semaglutide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F59011468"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">Glucagon-Like Peptide-1 Receptor Agonists Safety Update</span>
<span class="collapsible-date">January 2024</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). A preliminary evaluation has not found evidence that the use of these medicines causes suicidal thoughts or actions, but the FDA is continuing to investigate this issue. Patients should not stop taking GLP-1 RAs without consulting their health care provider. Health care providers should monitor for and advise patients using GLP-1 RAs to report new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior.</p>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Fupdate-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type&amp;token=miTanb%2Bz8Mpo90N4aa9rnBvzPyMcyGMouSYn352zIq27XyRAnm%2BDWunTXNDIRGRVPdvEcJ4t0dBZwKHPsWODdcKNBqg8p81GHTpH2D6qQhfyYSllM0BIXdmigC6Atf7BXgPxeZTU1rPJai25j9dr%2BiXxmVJc5lhSTyKtYrSUSj8%3D&amp;TOPIC_ID=115980" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F50835341"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of thyroid C-cell tumors:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.</p>
<p style="text-indent:-2em;margin-left:2em;">Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with semaglutide.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50847653"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ozempic (0.25 or 0.5 MG/DOSE);</li>
<li>Ozempic (1 MG/DOSE);</li>
<li>Ozempic (2 MG/DOSE);</li>
<li>Rybelsus;</li>
<li>Wegovy</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872343"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ozempic (0.25 or 0.5 MG/DOSE);</li>
<li>Ozempic (1 MG/DOSE);</li>
<li>Rybelsus</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50835350"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F50876261"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>May require a dose reduction of insulin and/or insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment (Ozempic, Rybelsus): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an adjunctive agent or alternative monotherapy for patients in whom initial therapy with lifestyle intervention and metformin failed <b>or</b> those who cannot take metformin. May be preferred in patients who have or are at risk for atherosclerotic cardiovascular disease (Ozempic only), when weight loss is desired, and/or in patients with an HbA<sub>1c</sub> relatively far from goal (eg, HbA<sub>1c</sub> 9% to 10%) and type 1 diabetes is not likely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.3','lexi-content-ref-27633186','lexi-content-ref-Wexler.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.3','lexi-content-ref-27633186','lexi-content-ref-Wexler.2022'])">Ref</a></span>). Consider slower dose titration in patients with diabetic retinopathy to avoid exacerbating the condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dungan.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dungan.2022'])">Ref</a></span>). Due to lack of additive glycemic benefit, avoid concomitant use with a dipeptidyl peptidase-4 inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30291106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30291106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b>
<b>Note:</b> Administer ≥30 minutes before the first food, beverage, or other medications of the day.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 3 mg once daily for 30 days, then increase to 7 mg once daily; may increase to 14 mg once daily after 30 days on the 7 mg dose if needed to achieve glycemic goals. <b>Note:</b> The lower initial dose (3 mg daily) is intended to reduce GI symptoms; it does not provide effective glycemic control.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Missed dose: </i>Missed dose should be skipped; resume at the next scheduled dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Initial: 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly. May increase to 1 mg once weekly after 4 weeks on the 0.5 mg/week dose if needed to achieve glycemic goals; may increase further to 2 mg once weekly after 4 weeks on the 1 mg/week dose if needed to achieve glycemic goals (maximum: 2 mg/week). <b>Note:</b> The lower initial dose (0.25 mg weekly) is intended to reduce GI symptoms; it does not provide effective glycemic control. If changing the day of administration is necessary, allow at least 48 hours between 2 doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed dose: </i>Missed dose should be administered as soon as possible within 5 days; resume usual schedule thereafter. If &gt;5 days have elapsed, skip the missed dose and resume administration at the next scheduled weekly dose.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Conversion from oral semaglutide to Ozempic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If current oral dose is 7 mg once daily:</i> There is no equivalent SUBQ dose provided in the manufacturer's labeling; some experts convert to 0.5 mg SUBQ once weekly, beginning the day after the last oral dose; monitor glucose more closely during transition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dungan.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dungan.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If current oral dose is 14 mg once daily:</i> Convert to 0.5 mg SUBQ once weekly, beginning the day after the last oral dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion from Ozempic to oral semaglutide:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If current SUBQ dose is 0.5 mg once weekly:</i> Convert to 7 or 14 mg orally once daily, beginning within 7 days of the last injection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If current SUBQ dose is 1 mg once weekly:</i> There is no equivalent oral dose provided in the manufacturer's labeling; some experts convert to 14 mg orally once daily, beginning within 7 days of the last injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dungan.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dungan.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24267291-50a0-4efc-98cd-a5840a223299">Weight management, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, chronic (Wegovy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an adjunct to diet and exercise in patients with a BMI ≥30 kg/m<sup>2</sup>, or in patients with a BMI ≥27 kg/m<sup>2</sup> and ≥1 weight-associated comorbidity (eg, hypertension, dyslipidemia).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Initiate and adjust dose using the following schedule: In patients who do not tolerate a dosage increase, consider delaying the increase for an additional 4 weeks:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Week 1 through week 4</i>
<i>:</i> 0.25 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Week 5 through week 8:</i> 0.5 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Week 9 through week 12:</i> 1 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Week 13 through week 16:</i> 1.7 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Week 17 and thereafter (maintenance dosage):</i> 2.4 mg once weekly (preferred regimen); if not tolerated, may use an alternative maintenance dosage of 1.7 mg once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> The manufacturer recommends discontinuing therapy in patients who cannot tolerate the 1.7 mg/week dosage; however, some patients may achieve goal weight loss on a submaximal dose and may continue on the maximum tolerated dose (even if &lt;1.7 mg/week) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36273831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36273831'])">Ref</a></span>). Consider discontinuation if at least 5% of baseline body weight loss has not been achieved within 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed dose:</i> Missed dose should be administered as soon as possible within 5 days; resume usual schedule thereafter. If &gt;5 days have elapsed, skip the missed dose and resume administration at the next scheduled weekly dose. If 2 or more consecutive doses are missed, resume dosing as scheduled; alternatively, may reinitiate dosage adjustment schedule.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991054"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29623579','lexi-content-ref-28349386','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29623579','lexi-content-ref-28349386','lexi-content-ref-Manu.1'])">Ref</a></span>). Use caution when initiating or escalating doses; new-onset or worsening of existing renal failure has been reported, most commonly in patients experiencing volume depletion from GI losses (eg, vomiting, diarrhea, dehydration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary; use with caution due to limited clinical evidence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzable: No dosage adjustment necessary; use with caution due to limited clinical evidence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988294"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F50876273"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F57634945"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="140434" href="/d/html/140434.html" rel="external">see "Semaglutide: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24267291-50a0-4efc-98cd-a5840a223299">Weight management, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, chronic</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> For use as adjunct therapy with a reduced-calorie diet and increased physical activity in pediatric patients; only use in patients 12 to &lt;18 years of age with an initial BMI in the 95th percentile or higher for age and sex or patients ≥18 years with a BMI ≥30 kg/m<sup>2</sup> or patients with a BMI ≥27 kg/m<sup>2</sup> and ≥1 weight-associated comorbidity (eg, dyslipidemia, hypertension, type 2 diabetes mellitus). To minimize GI effects, escalate dose slowly over at least 16 weeks to reach maintenance dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Wegovy: SUBQ:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dose escalation: </i></p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Week of Semaglutide </b>(Wegovy) <b>Therapy</b>
<sup>a</sup></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Dose (mg) Once Weekly</b>
<sup>a</sup></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>a</sup> If a dose is not tolerated, consider delaying further dose increases for 4 weeks.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">Weeks 1 through 4</p></td>
<td align="left">
<p style="text-indent:0em;">0.25 mg once weekly</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Weeks 5 through 8</p></td>
<td align="left">
<p style="text-indent:0em;">0.5 mg once weekly</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Weeks 9 though 12</p></td>
<td align="left">
<p style="text-indent:0em;">1 mg once weekly</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Weeks 13 through 16</p></td>
<td align="left">
<p style="text-indent:0em;">1.7 mg once weekly</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥Week 17</p></td>
<td align="left">
<p style="text-indent:0em;">See maintenance dose</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents &lt;18 years: Wegovy: SUBQ: 2.4 mg once weekly. Per the manufacturer, if maintenance dose of 2.4 mg is not tolerated, decrease to 1.7 mg once weekly; if the weekly dose of 1.7 mg is not tolerated, discontinue semaglutide therapy; however, in the STEP TEENS trial, patients could continue on their maximum tolerated dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36322838','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36322838','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥18 years: Wegovy: SUBQ: 2.4 mg once weekly. If not tolerated, may temporarily decrease dosage to a weekly dose of 1.7 mg for up to 4 additional weeks, then increase to 2.4 mg once weekly; per the manufacturer, therapy should be discontinued in patients who cannot tolerate the 2.4 mg/week dosage.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F57634980"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Wegovy: SUBQ:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild to severe impairment: No dosage adjustment necessary. Use caution when initiating or escalating doses; new-onset acute kidney injury or worsening of existing kidney failure has been reported, most commonly in patients experiencing volume depletion from GI losses (eg, vomiting, diarrhea, dehydration).</p></div>
<div class="block dohp drugH1Div" id="F57634981"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents: Wegovy: SUBQ: No dosage adjustment necessary.</p></div>
<div class="block arsc drugH1Div" id="F55596286"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute kidney injury</b> (AKI), which sometimes requires dialysis, has been reported with semaglutide and other glucagon-like peptide-1 receptor agonists. According to the manufacturer, AKI secondary to semaglutide was seen mostly in patients who had experienced nausea, vomiting, diarrhea, or dehydration. In a post-hoc analysis of multiple clinical trials, there was no difference in the incidence of acute kidney failure between semaglutide and comparators, including placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32971040']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32971040'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; exact mechanism is unknown. Pre-renal AKI may occur due to dehydration and volume contraction secondary to gastrointestinal symptoms (eg, nausea, vomiting, diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; because the mechanism is thought to be related to volume contraction, timing may be dependent on gastrointestinal symptoms, initiation or dosage adjustment of concomitant medications, and/or comorbid conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Volume contraction (eg, during periods of severe vomiting or diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Co-administration of medications known to result in kidney injury during episodes of dehydration (eg, drugs that inhibit the renin-angiotensin system) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Diabetic retinopathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">An increased incidence of <b>diabetic retinopathy </b>complications (DRCs) was noted during the SUSTAIN-6 study, a clinical trial evaluating the impact of SUBQ semaglutide on cardiovascular outcomes in patients with type 2 diabetes; complications included vitreous hemorrhage, onset of diabetes-related blindness, and the need for treatment with an intravitreal agent or retinal photocoagulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27633186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27633186'])">Ref</a></span>). In a separate analysis of SUSTAIN clinical trial data, the effect was reported to be mainly observed in patients with preexisting diabetic retinopathy (DR) and primarily attributable to the magnitude and rapidity of reduction in HbA<sub>1c</sub> during the first 16 weeks of the trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29178519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29178519'])">Ref</a></span>). Clinicians should note that this effect has been observed with SUBQ semaglutide, exenatide, and dulaglutide but not other glucagon-like peptide-1 receptor agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31189511','lexi-content-ref-27633186','lexi-content-ref-27295427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31189511','lexi-content-ref-27633186','lexi-content-ref-27295427'])">Ref</a></span>); trials are underway to better understand the long-term effects of semaglutide on diabetic eye disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31422062','lexi-content-ref-32799379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31422062','lexi-content-ref-32799379'])">Ref</a></span>). Oral semaglutide has not been associated with an increased incidence of DRC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31637820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31637820'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; in general, worsening of preexisting DR is a known consequence of rapid improvement of hyperglycemia, especially in patients with uncontrolled diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28533296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28533296'])">Ref</a></span>). Although unlikely, a direct toxic effect or potential angiogenic action of semaglutide has not been ruled out (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28533296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28533296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; the increased incidence of DRC during the SUSTAIN-6 study may be attributed to the reduction in HbA<sub>1c</sub> at week 16 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27633186','lexi-content-ref-29178519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27633186','lexi-content-ref-29178519'])">Ref</a></span>); however, clinicians should note that DR is a progressive condition, and the onset of DRCs may vary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting DR (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29178519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29178519'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Large (&gt;1.5%) and rapid (≤16 weeks) decline in HbA<sub>1c</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29178519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29178519'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gallbladder disease</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallbladder disease</b> and <b>biliary tract disease</b>, including <b>cholelithiasis</b> and <b>cholecystitis</b>, have been reported with glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001','lexi-content-ref-27633186','lexi-content-ref-28110911']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001','lexi-content-ref-27633186','lexi-content-ref-28110911'])">Ref</a></span>); some have required hospitalization or cholecystectomy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27478902','lexi-content-ref-35344001','lexi-content-ref-26132939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27478902','lexi-content-ref-35344001','lexi-content-ref-26132939'])">Ref</a></span>). Resolution of biliary stones following discontinuation has been documented with other GLP-1 receptor agonists (eg, liraglutide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25725635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25725635'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>); not fully understood. Animal studies and in vitro data have demonstrated that GLP-1 enhances the proliferation and functional activity of cholangiocytes, which may result in gallbladder diseases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17631146','lexi-content-ref-18829977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17631146','lexi-content-ref-18829977'])">Ref</a></span>). Some authors have postulated a change in bile acid production and secretion, suppressed secretion of cholecystokinin, decreased gallbladder emptying, prolonged gallbladder refilling, weight loss, or potentially a combination of these factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30137354','lexi-content-ref-31399438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30137354','lexi-content-ref-31399438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>); an increased risk was seen following &gt;26 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (eg, ≥1 mg SUBQ) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of treatment (eg, &gt;26 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35344001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35344001'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Substantial or rapid weight loss</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">GI effects, mainly <b>abdominal pain</b>, <b>constipation</b>, <b>diarrhea</b>, <b>nausea</b>, and <b>vomiting</b>, are the most common adverse reactions associated with glucagon-like peptide-1 receptor agonists, including semaglutide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27981757','lexi-content-ref-33199417','lexi-content-ref-25375397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27981757','lexi-content-ref-33199417','lexi-content-ref-25375397'])">Ref</a></span>). <b>Decreased appetite</b>, <b>dysgeusia</b>, and <b>dyspepsia</b> have also been reported. GI effects tend to occur during dose escalation and decrease over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21975753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21975753'])">Ref</a></span>); may result in treatment discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">Rates of GI effects were shown to be similar between oral and once-weekly semaglutide 1 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29049653']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29049653'])">Ref</a></span>); high-dose once-weekly semaglutide (2.4 mg/week) may result in higher incidences of GI effects. In the SUSTAIN-7 trial comparing once-weekly semaglutide to once-weekly dulaglutide, rates of GI effects were similar for both doses of semaglutide (0.5 mg and 1 mg) and high-dose dulaglutide (1.5 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29397376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29397376'])">Ref</a></span>). The SUSTAIN-3 trial, which evaluated once-weekly semaglutide 1 mg and once-weekly exenatide 2 mg, showed a higher rate of GI effects with semaglutide treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29246950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29246950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; however, the exact mechanism is not fully understood. May be a result of delayed gastric emptying or activation of centers involved in appetite regulation, satiety, and nausea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26177483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26177483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; nausea, vomiting, and diarrhea are most common soon after initiation (eg, the first 4 weeks of treatment) and during dose escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21975753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21975753'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose; generally greater with higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid titration</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, immediate hypersensitivity reactions, including <b>anaphylaxis</b> and <b>angioedema</b>, have been reported with glucagon-like peptide-1 (GLP-1) receptor agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28349386','lexi-content-ref-30350785','lexi-content-ref-25439386','lexi-content-ref-31806579','lexi-content-ref-31296642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28349386','lexi-content-ref-30350785','lexi-content-ref-25439386','lexi-content-ref-31806579','lexi-content-ref-31296642'])">Ref</a></span>). Exendin-based GLP-1 receptor agonists (eg, exenatide, lixisenatide) are associated with a doubling of reporting odds of anaphylactic reaction, compared with human-analogue GLP-1 receptor agonists (eg, liraglutide, dulaglutide, semaglutide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31806579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31806579'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; immunologic</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: IgE-antibodies are formed against a drug allergen following initial exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-30350785','lexi-content-ref-25439386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-30350785','lexi-content-ref-25439386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate hypersensitivity reactions: Rapid; generally occurs within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-31296642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-31296642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity between GLP-1 receptor agonists is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32301438','lexi-content-ref-31296642','lexi-content-ref-Steveling.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32301438','lexi-content-ref-31296642','lexi-content-ref-Steveling.2014'])">Ref</a></span>). Until further studies are available, semaglutide should be used with caution in patients with a history of anaphylaxis or angioedema to other GLP-1 receptor agonists. Skin tests have been used in patients with histories of immediate hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31296642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31296642'])">Ref</a></span>) and delayed hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32301438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32301438'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Medullary thyroid carcinoma</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In the early stages of drug development, thyroid C-cell tumors were noted to have developed during animal studies with semaglutide. It is unknown whether semaglutide causes thyroid C-cell tumors in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. According to the manufacturer, human cases of medullary thyroid carcinoma (MTC) have been reported with liraglutide, another glucagon-like peptide-1 (GLP-1) receptor agonist.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; animal studies have shown dose-dependent and treatment duration-dependent harmful effects in rodents but not primates, thereby indicating that proliferative C-cell effects of liraglutide may be rodent specific. Humans have far fewer C cells than rodents, and expression of the GLP-1 receptor in human C cells is very low (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20203154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20203154'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with a personal or family history of MTC or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2) may be at an increased risk</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pancreatitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>acute pancreatitis</b> (including <b>hemorrhagic pancreatitis</b> and <b>necrotizing pancreatitis</b> with some fatalities), chronic pancreatitis, and pancreatic adenocarcinoma have been reported with use of incretin-based therapies (eg, dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like peptide-1 [GLP-1] receptor agonists) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010561','lexi-content-ref-21334333','lexi-content-ref-FDA.2013','lexi-content-ref-24702687','lexi-content-ref-23440284']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010561','lexi-content-ref-21334333','lexi-content-ref-FDA.2013','lexi-content-ref-24702687','lexi-content-ref-23440284'])">Ref</a></span>). Acute pancreatitis was observed with semaglutide at rates similar to placebo during the SUSTAIN-6 trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27633186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27633186'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Causality has not been firmly established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24571751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24571751'])">Ref</a></span>). GLP-1 receptor agonists directly stimulate GLP-1 receptors in pancreatic islet beta cells and exocrine duct cells, which may cause an overgrowth of the cells that cover the smaller ducts, thereby resulting in hyperplasia, increased pancreatic weight, duct occlusion, back pressure, and subsequent acute or chronic pancreatic inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27883260','lexi-content-ref-25633664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27883260','lexi-content-ref-25633664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Not well characterized.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with a prior history of pancreatitis may be at an increased risk for acute pancreatitis.</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with acute pancreatitis due to any cause are at an increased risk for progression to recurrent acute pancreatitis and then to chronic pancreatitis; patients with chronic pancreatitis are at an increased risk for pancreatic cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23622135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23622135'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Risk factors for pancreatitis due to any cause include, but are not limited to, hypertriglyceridemia, cholelithiasis, alcohol use, and obesity.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F50899116"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (adolescents and adults: 6% to 20%)<span class="lexi-table-link-container"> (<a aria-label="Abdominal Pain table link" class="lexi-table-link" data-table-id="lexi-content-abdominal-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abdominal-pain')">table 1</a>)</span><span class="table-link" style="display:none;">Abdominal Pain</span>, constipation (oral: 5% to 6%; SUBQ: adolescents: 6%; adults: 3% to 24%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 2</a>)</span><span class="table-link" style="display:none;">Constipation</span>, diarrhea (oral: 9% to 10%; SUBQ: adolescents and adults: 9% to 30%)<span class="lexi-table-link-container"> (<a aria-label="Diarrhea table link" class="lexi-table-link" data-table-id="lexi-content-diarrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diarrhea')">table 3</a>)</span><span class="table-link" style="display:none;">Diarrhea</span>, nausea (oral: 11% to 20%; SUBQ: adolescents and adults: 16% to 44%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 4</a>)</span><span class="table-link" style="display:none;">Nausea</span>, vomiting (oral: 6% to 8%; SUBQ: adolescents: 36%, adults: 5% to 24%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 5</a>)</span><span class="table-link" style="display:none;">Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abdominal Pain" frame="border" id="lexi-content-abdominal-pain" rules="all">
<caption style="text-align:center;">
<b>Semaglutide: Adverse Reaction: Abdominal Pain</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">67</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,116</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,261</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">260</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">261</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Semaglutide: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">67</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,116</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,261</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">260</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">261</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diarrhea" frame="border" id="lexi-content-diarrhea" rules="all">
<caption style="text-align:center;">
<b>Semaglutide: Adverse Reaction: Diarrhea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">67</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,116</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,261</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">260</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">261</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Semaglutide: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">67</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">44%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,116</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,261</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">261</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">260</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Semaglutide: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">36%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">67</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,116</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,261</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">261</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">260</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (SUBQ: 11%), headache (SUBQ: adolescents and adults: 14% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (SUBQ: adolescents: 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (SUBQ: adolescents and adults: 1% to 2%; including orthostatic hypotension)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (SUBQ: adolescents and adults: 3% to 4%), skin rash (SUBQ: adolescents: 3%), urticaria (SUBQ: adolescents: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetic retinopathy (complications: 3% to 7%; vitreous hemorrhage: 1%; blindness: &lt;1%) (Marso 2016a), hypoglycemia (SUBQ: 2% to 6%), severe hypoglycemia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension (2% to 7%), cholelithiasis (adolescents and adults: 0% to 4%)<span class="lexi-table-link-container"> (<a aria-label="Cholelithiasis table link" class="lexi-table-link" data-table-id="lexi-content-cholelithiasis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-cholelithiasis')">table 6</a>)</span><span class="table-link" style="display:none;">Cholelithiasis</span>, decreased appetite (oral: 6% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Appetite table link" class="lexi-table-link" data-table-id="lexi-content-decreased-appetite" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-appetite')">table 7</a>)</span><span class="table-link" style="display:none;">Decreased Appetite</span>, dysgeusia (SUBQ: ≤2%), dyspepsia (oral: 0.6% to 3%; SUBQ: 3% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Dyspepsia table link" class="lexi-table-link" data-table-id="lexi-content-dyspepsia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dyspepsia')">table 8</a>)</span><span class="table-link" style="display:none;">Dyspepsia</span>, eructation (adolescents and adults: ≤7%), flatulence (1% to 6%), gastritis (2% to 4%), gastroenteritis (SUBQ: adolescents and adults: 6% to 7%), gastroesophageal reflux disease (adolescents and adults: 2% to 5%), viral gastroenteritis (SUBQ: 4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Cholelithiasis" frame="border" id="lexi-content-cholelithiasis" rules="all">
<caption style="text-align:center;">
<b>Semaglutide: Adverse Reaction: Cholelithiasis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">133</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">67</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,116</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,261</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">260</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">261</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Appetite" frame="border" id="lexi-content-decreased-appetite" rules="all">
<caption style="text-align:center;">
<b>Semaglutide: Adverse Reaction: Decreased Appetite</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dyspepsia" frame="border" id="lexi-content-dyspepsia" rules="all">
<caption style="text-align:center;">
<b>Semaglutide: Adverse Reaction: Dyspepsia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Semaglutide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2.4 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,116</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,261</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">260</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg/week</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">SUBQ</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">261</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">262</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14 mg/day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">356</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">362</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (SUBQ: adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (SUBQ: adolescents: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (SUBQ: adolescents: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (SUBQ: adolescents: 4%), dizziness (SUBQ: adolescents and adults: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Sprain (ligament: SUBQ: adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sinusitis (SUBQ: adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis (including hemorrhagic pancreatitis, necrotizing pancreatitis) (Marso 2016a), cholecystitis (SUBQ: adolescents and adults)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Discomfort at injection site (SUBQ), erythema at injection site (SUBQ)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Hemorrhoids (SUBQ), increased serum amylase (adolescents and adults: mean increase from baseline of 10% to 16%), increased serum lipase (adolescents and adults: mean increase from baseline of 22% to 39%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any formulation or population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased heart rate (Demmel 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous pemphigoid (Burruss 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Biliary tract disease (He 2022), cholecystectomy, delayed gastric emptying (Fujino 2023), gallbladder disease (He 2022), intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic injury (increased serum alkaline phosphatase, jaundice, and biliary cirrhosis) (Ma 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Pradhan 2020), angioedema (Marbury 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Borkum 2022), acute kidney injury (Filippatos 2014, Leehey 2021)</p></div>
<div class="block coi drugH1Div" id="F50835438"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to semaglutide or any component of the formulation; personal or family history of medullary thyroid carcinoma (MTC); patients with multiple endocrine neoplasia syndrome type 2 (MEN2)</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy; breastfeeding</p></div>
<div class="block war drugH1Div" id="F50876206"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric effects: Suicidal behavior has been reported with other medications used for weight management. Avoid use in patients with history of suicidal attempts or active suicidal ideation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">- Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy, and closely monitor the patient for the duration of therapy; acute and chronic kidney failure exacerbation may occur. A majority of cases occurred in patients with nausea, vomiting, diarrhea, and/or dehydration. Nausea is common and fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">- Excessive glucagon-like peptide-1 exposure: Closely monitor for efficacy and assess for signs and symptoms of pancreatitis if therapy is initiated after surgery; gastric bypass and sleeve gastrectomy (but not gastric band) significantly increase endogenous postprandial GLP-1 concentrations (Korner 2009; Peterli 2012). Administration of exogenous GLP-1 agonists may be redundant to surgery effects.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed gastric emptying: Semaglutide slows gastric emptying, which may alter the absorption of other medications. Monitor narrow therapeutic index medications for increased or decreased response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple dose injection pens (Ozempic): According to the CDC, pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use:</p>
<p style="text-indent:-2em;margin-left:6em;">- Diabetes mellitus: Do not use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; not a substitute for insulin.</p>
<p style="text-indent:-2em;margin-left:6em;">- Weight loss: Safety and effectiveness in combination with other products intended for weight loss have not been established.</p></div>
<div class="block foc drugH1Div" id="F50847654"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Wegovy: 0.25 mg/0.5 mL (0.5 mL); 0.5 mg/0.5 mL (0.5 mL); 1 mg/0.5 mL (0.5 mL); 1.7 mg/0.75 mL (0.75 mL); 2.4 mg/0.75 mL (0.75 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ozempic (0.25 or 0.5 MG/DOSE): 2 mg/3 mL (3 mL); 0.25 mg or 0.5 mg per dose [2 mg/1.5 mL] (1.5 mL [DSC]) [contains phenol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ozempic (1 MG/DOSE): 1 mg per dose [4 mg/3 mL] (3 mL); 1 mg per dose [2 mg/1.5 mL] (1.5 mL [DSC]) [contains phenol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ozempic (2 MG/DOSE): 8 mg/3 mL (3 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rybelsus: 3 mg, 7 mg, 14 mg</p></div>
<div class="block geq drugH1Div" id="F50847652"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51083822"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Wegovy Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg/0.5 mL (per 0.5 mL): $404.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/0.5 mL (per 0.5 mL): $404.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/0.5 mL (per 0.5 mL): $404.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.7 mg/0.75 mL (per 0.75 mL): $404.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.4 mg/0.75 mL (per 0.75 mL): $404.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Ozempic (0.25 or 0.5 MG/DOSE) Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/3 mL (per mL): $387.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Ozempic (1 MG/DOSE) Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/3 mL (per mL): $387.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Ozempic (2 MG/DOSE) Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg/3 mL (per mL): $387.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Rybelsus Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $38.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7 mg (per each): $38.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">14 mg (per each): $38.74</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872344"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ozempic (0.25 or 0.5 MG/DOSE): 2 mg/3 mL (3 mL); 0.25 mg or 0.5 mg per dose [2 mg/1.5 mL] (1.5 mL) [contains phenol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ozempic (1 MG/DOSE): 1 mg per dose [4 mg/3 mL] (1.5 mL) [contains phenol, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rybelsus: 3 mg, 7 mg, 14 mg</p></div>
<div class="block adm drugH1Div" id="F50880445"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer on an empty stomach, ≥30 minutes before the first food, beverage, or other oral medications of the day with ≤4 oz of plain water only. The manufacturer recommends eating 30 to 60 minutes after the dose. Swallow tablets whole; do not split, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Administer by SUBQ injection into the abdomen, thigh, or upper arm at any time of day on the same day each week, with or without food. If changing the day of administration is necessary, allow ≥48 hours between 2 doses. Rotate injection sites weekly if injecting in the same area of the body. Do not mix with other products (administer as separate injections). Avoid adjacent injections if administering other agents in the same area of the body. Solution should be clear; do not use if particulate matter and coloration are seen.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ozempic: </i>For each new prefilled pen, prime the needle before the first injection by turning the dose selector to the flow check symbol and injecting into the air (priming is not required for subsequent injections). Use a new needle for each injection. Once injected, continue to depress the button until the dial has returned to 0 <b>and</b> for an additional 6 seconds. Then, remove the needle from the skin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Wegovy:</i> After removal of the pen cap, the needle will be hidden inside the needle cover. To begin injection, press the needle cover firmly against the skin. Once injected, continue to press the device against the skin until the yellow bar has stopped moving. Then, remove the needle from the skin.</p></div>
<div class="block admp drugH1Div" id="F57634982"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Wegovy: SUBQ: Administer by SUBQ injection into the abdomen (do not inject within 2 inches of belly button), thigh, or upper arm at any time of day on the same day each week, with or without food. Solution should be clear; do not use if particulate matter and coloration are seen; do not mix with other products. After removal of the pen cap, the needle will be hidden inside the needle cover. To begin injection, press the needle cover firmly against the skin, continue to press the device against the skin until the yellow bar has stopped moving. Then, slowly remove the needle from the skin and dispose of pen. Rotate injection sites weekly if injecting in the same area of the body. Do not inject into areas that are tender, bruised, red, or hard, or have scars or stretch marks. If changing the day of administration is necessary, allow ≥2 days between 2 doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If one dose is missed and the next scheduled dose is &gt;2 days away, administer the missed dose as soon as possible. If one dose is missed and the next scheduled dose is &lt;2 days away, do not administer the missed dose and resume dosing on the regularly scheduled day of the week. If 2 or more doses are missed, may either resume at the next regularly scheduled day of the week or may consider reinitiating semaglutide and follow the dose escalation schedule.</p></div>
<div class="block hazard drugH1Div" id="F50876215"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the National Institute for Occupational Safety and Health (NIOSH) (2016) list; however, it may meet the criteria for a hazardous drug. Semaglutide may cause carcinogenicity, teratogenicity, and reproductive toxicity.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F52942386"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Ozempic: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F209637s012lbl.pdf%23page%3D27&amp;token=2ucCJN8WXq1rxB1u9Dop4LN0c3YIisBoWwJ7qtyz6ABpdL%2FKAplIEIXAm3pUBItVal2Y03Y3hCrKvYhO1H0G0lNFiKffcguKsh9%2BX%2BZRpRphuF4t0qT3%2FC%2BQqeFmZpR4&amp;TOPIC_ID=115980" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s012lbl.pdf#page=27</a></p>
<p style="text-indent:-2em;margin-left:4em;">Rybelsus: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F213051s012lbl.pdf%23page%3D24&amp;token=bjJcAT%2BGwaLOQVedXDCm7s%2FCLNVFy9O7IIwBrHxDRFuZR9EwCVtx%2BakYkTjZje6t%2Fm8hQJ%2FLe9cevorWx1%2Bxdzuloum%2B7w4CGE9iAhgXMmoyZwBUyNM0C%2FYBBfYVAp%2BF&amp;TOPIC_ID=115980" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213051s012lbl.pdf#page=24</a></p>
<p style="text-indent:-2em;margin-left:4em;">Wegovy: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F215256s007lbl.pdf%23page%3D34&amp;token=HT1wjCWvBm3eWWkGgYeXKF5MA%2Fpo%2FowG9GtPXLHhO%2FxJjbICjyoU%2ByldY7ChkiGMHbYe1i4%2Fq2wO4iBIr1iIJSg%2BwY3IsaoUBVgrsD9ww4A%2BQcjW8HWc3UsB3vCiJw13&amp;TOPIC_ID=115980" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf#page=34</a></p></div>
<div class="block use drugH1Div" id="F50835349"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment (Ozempic, Rybelsus): </b>As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; risk reduction of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (Ozempic only).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, chronic (Wegovy):</b> As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ≥30 kg/m<sup>2</sup> (obesity), or ≥27 kg/m<sup>2</sup> (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, dyslipidemia) and pediatric patients ≥12 years of age with an initial BMI at the ≥95th percentile standardized for age and sex (obesity).</p></div>
<div class="block mst drugH1Div" id="F50901429"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cross-contamination may occur if pens are shared among multiple patients. Steps should be taken to prohibit sharing of pens.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F50871913"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F50871910"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May diminish the therapeutic effect of Semaglutide. Semaglutide may increase the serum concentration of Furosemide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: Semaglutide may enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Insulins.  Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Semaglutide may increase the serum concentration of Levothyroxine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Liraglutide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglitinides: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Meglitinides.  Management: Consider meglitinide dose reductions when used in combination with glucagon-like peptide-1 agonists, particularly when also used with basal insulin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tirzepatide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53514495"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Glucagon-like peptide-1 (GLP-1) receptor agonists are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020)</p>
<p style="text-indent:0em;margin-top:2em;">When used for the treatment of diabetes mellitus or weight loss management, semaglutide should be discontinued for ≥2 months prior to becoming pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Medications for weight loss therapy are not recommended at conception (ACOG 2021).</p></div>
<div class="block pri drugH1Div" id="F50876204"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Poorly controlled diabetes during pregnancy is associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia (ACOG 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than semaglutide are currently recommended to treat diabetes mellitus during pregnancy (ADA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of adverse maternal and fetal outcomes is associated with obesity; however, medications for weight loss therapy are not recommended during pregnancy (ACOG 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to semaglutide is ongoing. Health care providers are encouraged to enroll patients exposed to semaglutide during pregnancy in the registry by contacting Novo Nordisk (1-877-390-2760 or https://www.wegovypregnancyregistry.com). Patients may also enroll themselves.</p></div>
<div class="block brc drugH1Div" id="F50876205"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if semaglutide is present in breast milk. The oral formulation also contains salcaprozate sodium (SNAC); it is not known if SNAC is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy with injectable semaglutide should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Breastfeeding during therapy with oral semaglutide is not recommended due to the unknown risks associated with potential accumulation of SNAC in the infant.</p></div>
<div class="block dic drugH1Div" id="F53765709"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach, ≥30 minutes before the first food, beverage, or other oral medications of the day with ≤4 oz of plain water only. The manufacturer recommends eating 30 to 60 minutes after the dose.</p></div>
<div class="block mop drugH1Div" id="F50880503"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Plasma glucose (individualize frequency based on treatment regimen, hypoglycemia risk, and other patient-specific factors) (ADA 2023); heart rate and body weight (if used for chronic weight management); renal function (especially when initiating therapy or increasing doses in patients reporting severe adverse GI reactions); signs/symptoms of pancreatitis (eg, persistent severe abdominal pain which may radiate to the back and which may or may not be accompanied by vomiting); triglycerides; signs/symptoms of gallbladder disease; worsening of diabetic retinopathy (particularly in those with a prior history of the disease).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HbA<sub>1c</sub>:</i> Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note:</b> In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Routine monitoring of serum calcitonin or using thyroid ultrasound monitoring is of uncertain value for early detection of medullary thyroid carcinoma in patients treated with semaglutide.</p></div>
<div class="block rer drugH1Div" id="F50889224"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults (AACE [Samson 2023]; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note</b>
<b>: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note: </b>Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F50876217"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Semaglutide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist that increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, slows gastric emptying; also acts in the areas of the brain involved in regulation of appetite and caloric intake.</p></div>
<div class="block phk drugH1Div" id="F50876237"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Oral: ~8 L; SUBQ: ~12.5 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99% to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Proteolytic cleavage of the peptide backbone with sequential beta-oxidation of the fatty acid sidechain.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~0.4% to 1%; SUBQ: 89%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~1 week.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Oral: 1 hour; SUBQ: 1 to 3 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~3% as unchanged drug), feces.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F52003568"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Orsema</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Rybelsus</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Rybelsus | Wegovy</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Wegovy</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Rybelsus</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus | Wegovy flextouch</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ozempic (0.25 mg Dose) | Ozempic (0.5 mg Dose) | Ozempic (1 mg Dose) | Rybelsus | Wegovy | Wegovy Flextouch</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ozempic</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Rybelsus</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ozempic | Rybelsus</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29246950">
<a name="29246950"></a>Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. <i>Diabetes Care</i>. 2018;41(2):258-266. doi:10.2337/dc17-0417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/29246950/pubmed" id="29246950" target="_blank">29246950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23010561">
<a name="23010561"></a>Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. <i>Diabetes Res Clin Pract</i>. 2012;98(2):271-284. doi:10.1016/j.diabres.2012.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/23010561/pubmed" id="23010561" target="_blank">23010561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 201: Pregestational diabetes mellitus. <i>Obstet Gynecol</i>. 2018;132(6):e228-e248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34011890">
<a name="34011890"></a>American College of Obstetricians and Gynecologists’ (ACOG) Committee on Practice Bulletins–Obstetrics. Practice Bulletin No 230: Obesity in pregnancy. <i>Obstet Gynecol</i>. 2021;137(6):e128-e144. doi:10.1097/AOG.0000000000004395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/34011890/pubmed" id="34011890" target="_blank">34011890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.3">
<a name="ADA.3"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31637820">
<a name="31637820"></a>Avgerinos I, Michailidis T, Liakos A, et al. Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. <i>Diabetes Obes Metab</i>. 2020;22(3):335-345. doi:10.1111/dom.13899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/31637820/pubmed" id="31637820" target="_blank">31637820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20203154">
<a name="20203154"></a>Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. <i>Endocrinology</i>. 2010;151(4):1473-1486. doi:10.1210/en.2009-1272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/20203154/pubmed" id="20203154" target="_blank">20203154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36471818">
<a name="36471818"></a>Borkum M, Lau W, Blanco P, Farah M. Semaglutide-associated acute interstitial nephritis: a case report. <i>Kidney Med</i>. 2022;4(12):100561. doi:10.1016/j.xkme.2022.100561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/36471818/pubmed" id="36471818" target="_blank">36471818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34466645">
<a name="34466645"></a>Burruss CP, Jones JM, Burruss JB. Semaglutide-associated bullous pemphigoid. <i>JAAD Case Rep</i>. 2021;15:107-109. doi:10.1016/j.jdcr.2021.07.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/34466645/pubmed" id="34466645" target="_blank">34466645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32301438">
<a name="32301438"></a>Carvallo A, Silva C, Gastaminza G, D'Amelio CM. Delayed hypersensitivity reaction to liraglutide: a case report. <i>J Investig Allergol Clin Immunol</i>. 2020;30(5):367-369. doi:10.18176/jiaci.0521<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/32301438/pubmed" id="32301438" target="_blank">32301438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27979900">
<a name="27979900"></a>Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention. <a href="https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html" target="_blank">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html.</a> Updated January 5, 2012. Accessed December 7, 2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/27979900/pubmed" id="27979900" target="_blank">27979900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29049653">
<a name="29049653"></a>Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. <i>JAMA</i>. 2017;318(15):1460-1470. doi:10.1001/jama.2017.14752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/29049653/pubmed" id="29049653" target="_blank">29049653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669‐2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29799100">
<a name="29799100"></a>Demmel V, Sandberg-Schaal A, Jacobsen JB, Golor G, Pettersson J, Flint A. No QTc prolongation with semaglutide: a thorough QT study in healthy subjects. <i>Diabetes Ther</i>. 2018;9(4):1441-1456. doi:10.1007/s13300-018-0442-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/29799100/pubmed" id="29799100" target="_blank">29799100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dungan.2022">
<a name="Dungan.2022"></a>Dungan K, DeSantis A. Glucagon-like peptide 1-based therapies for the treatment of type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24571751">
<a name="24571751"></a>Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. <i>N Engl J Med</i>. 2014;370(9):794-797. doi:10.1056/NEJMp1314078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/24571751/pubmed" id="24571751" target="_blank">24571751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32736942">
<a name="32736942"></a>Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. <i>Mayo Clin Proc</i>. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/32736942/pubmed" id="32736942" target="_blank">32736942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21334333">
<a name="21334333"></a>Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. <i>Gastroenterology</i>. 2011;141(1):150-156. doi:10.1053/j.gastro.2011.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/21334333/pubmed" id="21334333" target="_blank">21334333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27478902">
<a name="27478902"></a>Faillie JL, Yu OH, Yin H, et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. <i>JAMA Intern Med</i>. 2016;176(10):1474-1481. doi:10.1001/jamainternmed.2016.1531<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/27478902/pubmed" id="27478902" target="_blank">27478902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26177483">
<a name="26177483"></a>Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. <i>Rev Diabet Stud</i>. 2014;11(3-4):202-230. doi:10.1900/RDS.2014.11.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/26177483/pubmed" id="26177483" target="_blank">26177483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2013">
<a name="FDA.2013"></a>Food and Drug Administration. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Published March 14, 2013. Accessed March 12, 2021. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37602101">
<a name="37602101"></a>Fujino E, Cobb KW, Schoenherr J, Gouker L, Lund E. Anesthesia Considerations for a patient on semaglutide and delayed gastric emptying. <i>Cureus</i>. 2023;15(7):e42153. doi:10.7759/cureus.42153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/37602101/pubmed" id="37602101" target="_blank">37602101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31189511">
<a name="31189511"></a>Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet</i>. 2019;394(10193):121-130. doi:10.1016/S0140-6736(19)31149-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/31189511/pubmed" id="31189511" target="_blank">31189511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30137354">
<a name="30137354"></a>Gether IM, Nexøe-Larsen C, Knop FK. New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs. <i>J Clin Endocrinol Metab</i>. 2019;104(7):2463-2472. doi:10.1210/jc.2018-01008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/30137354/pubmed" id="30137354" target="_blank">30137354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24702687">
<a name="24702687"></a>Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. <i>Diabetes Obes Metab</i>. 2014;16(11):1041-1047. doi:10.1111/dom.12297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/24702687/pubmed" id="24702687" target="_blank">24702687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29623579">
<a name="29623579"></a>Granhall C, Søndergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. <i>Clin Pharmacokinet</i>. 2018;57(12):1571-1580. doi:10.1007/s40262-018-0649-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/29623579/pubmed" id="29623579" target="_blank">29623579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36273831">
<a name="36273831"></a>Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. <i>Gastroenterology</i>. 2022;163(5):1198-1225. doi:10.1053/j.gastro.2022.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/36273831/pubmed" id="36273831" target="_blank">36273831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35344001">
<a name="35344001"></a>He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. <i>JAMA Intern Med</i>. 2022;e220338. doi:10.1001/jamainternmed.2022.0338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/35344001/pubmed" id="35344001" target="_blank">35344001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27981757">
<a name="27981757"></a>Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. <i>Diabetes Obes Metab</i>. 2017;19(4):524-536. doi:10.1111/dom.12849<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/27981757/pubmed" id="27981757" target="_blank">27981757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27883260">
<a name="27883260"></a>Knapen LM, de Jong RG, Driessen JH, et al. Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study. <i>Diabetes Obes Metab</i>. 2017;19(3):401-411. doi:10.1111/dom.12833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/27883260/pubmed" id="27883260" target="_blank">27883260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25725635">
<a name="25725635"></a>Korkmaz H, Araz M, Alkan S, Akarsu E. Liraglutide-related cholelithiasis. <i>Aging Clin Exp Res</i>. 2015;27(5):751-753. doi:10.1007/s40520-015-0335-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/25725635/pubmed" id="25725635" target="_blank">25725635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi:10.1038/ijo.2009.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31422062">
<a name="31422062"></a>Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet Diabetes Endocrinol</i>. 2019;7(10):776-785. doi:10.1016/S2213-8587(19)30249-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/31422062/pubmed" id="31422062" target="_blank">31422062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33851124">
<a name="33851124"></a>Leehey DJ, Rahman MA, Borys E, Picken MM, Clise CE. Acute kidney injury associated with semaglutide. <i>Kidney Med</i>. 2021;3(2):282-285. doi:10.1016/j.xkme.2020.10.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/33851124/pubmed" id="33851124" target="_blank">33851124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LeRoith.2019">
<a name="LeRoith.2019"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520‐1574. doi:10.1210/jc.2019-00198</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36600793">
<a name="36600793"></a>Ma J, Mathur K, Muldoon JL, Ghabril M, Chalasani N, Vuppalanchi R. Progressive cholestasis and biliary cirrhosis after initiating oral semaglutide: report from the drug-induced liver injury network. <i>ACG Case Rep J</i>. 2022;9(12):e00922. doi:10.14309/crj.0000000000000922<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/36600793/pubmed" id="36600793" target="_blank">36600793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32971040">
<a name="32971040"></a>Mann JFE, Hansen T, Idorn T, et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. <i>Lancet Diabetes Endocrinol</i>. 2020;8(11):880-893. doi:10.1016/S2213-8587(20)30313-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/32971040/pubmed" id="32971040" target="_blank">32971040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28349386">
<a name="28349386"></a>Marbury TC, Flint A, Jacobsen JB, Derving Karsbøl J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. <i>Clin Pharmacokinet</i>. 2017;56(11):1381-1390. doi:10.1007/s40262-017-0528-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/28349386/pubmed" id="28349386" target="_blank">28349386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32799379">
<a name="32799379"></a>Marchand L, Luyton C, Bernard A. Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and long-term complications: FOCUS on retinopathy. <i>Diabet Med</i>. 2021;38(1):e14390. doi:10.1111/dme.14390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/32799379/pubmed" id="32799379" target="_blank">32799379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27633186">
<a name="27633186"></a>Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. <i>N Engl J Med</i>. 2016;375(19):1834‐1844. doi:10.1056/NEJMoa1607141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/27633186/pubmed" id="27633186" target="_blank">27633186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27295427">
<a name="27295427"></a>Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med</i>. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/27295427/pubmed" id="27295427" target="_blank">27295427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18829977">
<a name="18829977"></a>Marzioni M, Alpini G, Saccomanno S, et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. <i>Gut</i>. 2009;58(7):990-997. doi:10.1136/gut.2008.150870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/18829977/pubmed" id="18829977" target="_blank">18829977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17631146">
<a name="17631146"></a>Marzioni M, Alpini G, Saccomanno S, et al. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. <i>Gastroenterology</i>. 2007;133(1):244-255. doi:10.1053/j.gastro.2007.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/17631146/pubmed" id="17631146" target="_blank">17631146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31399438">
<a name="31399438"></a>Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. <i>Diabetes Care</i>. 2019;42(10):1912-1920. doi:10.2337/dc19-0415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/31399438/pubmed" id="31399438" target="_blank">31399438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30350785">
<a name="30350785"></a>Ornelas C, Caiado J, Lopes A, Pereira Dos Santos MC, Pereira Barbosa M. Anaphylaxis to long-acting release exenatide. <i>J Investig Allergol Clin Immunol</i>. 2018;28(5):332-334. doi:10.18176/jiaci.0274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/30350785/pubmed" id="30350785" target="_blank">30350785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ozempic.1">
<a name="Ozempic.1"></a>Ozempic (semaglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ozempic.2020.07">
<a name="Ozempic.2020.07"></a>Ozempic (semaglutide) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25439386">
<a name="25439386"></a>Pérez E, Martínez-Tadeo J, Callero A, Hernández G, Rodríguez-Plata E, García-Robaina JC. A case report of allergy to exenatide. <i>J Allergy Clin Immunol Pract</i>. 2014;2(6):822-823. doi:10.1016/j.jaip.2014.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/25439386/pubmed" id="25439386" target="_blank">25439386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi: 10.1007/s11695-012-0622-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26132939">
<a name="26132939"></a>Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. <i>N Engl J Med</i>. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/26132939/pubmed" id="26132939" target="_blank">26132939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31806579">
<a name="31806579"></a>Pradhan R, Montastruc F, Rousseau V, Patorno E, Azoulay L. Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. <i>Lancet Diabetes Endocrinol</i>. 2020;8(1):13-14. doi:10.1016/S2213-8587(19)30382-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/31806579/pubmed" id="31806579" target="_blank">31806579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33199417">
<a name="33199417"></a>Pratley RE, Aroda VR, Catarig AM, et al. Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 <i>post hoc</i> analyses. <i>BMJ Open</i>. 2020;10(11):e037883. doi:10.1136/bmjopen-2020-037883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/33199417/pubmed" id="33199417" target="_blank">33199417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29397376">
<a name="29397376"></a>Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. <i>Lancet Diabetes Endocrinol</i>. 2018;6(4):275-286. doi:10.1016/S2213-8587(18)30024-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/29397376/pubmed" id="29397376" target="_blank">29397376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rybelsus.1">
<a name="Rybelsus.1"></a>Rybelsus (semaglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rybelsus.1">
<a name="Rybelsus.1"></a>Rybelsus (semaglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rybelsus.2">
<a name="Rybelsus.2"></a>Rybelsus (semaglutide) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31296642">
<a name="31296642"></a>Shamriz O, NaserEddin A, Mosenzon O, Sviri S, Tal Y. Allergic reaction to exenatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists. <i>Diabetes Care</i>. 2019;42(9):e141-e142. doi:10.2337/dc19-0720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/31296642/pubmed" id="31296642" target="_blank">31296642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21975753">
<a name="21975753"></a>Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. <i>Cochrane Database Syst Rev</i>. 2011;2011(10):CD006423. doi:10.1002/14651858.CD006423.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/21975753/pubmed" id="21975753" target="_blank">21975753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28533296">
<a name="28533296"></a>Simó R, Hernández C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? <i>Diabetes</i>. 2017;66(6):1453-1460. doi:10.2337/db16-1364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/28533296/pubmed" id="28533296" target="_blank">28533296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23440284">
<a name="23440284"></a>Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. <i>JAMA Intern Med</i>. 2013;173(7):534-539. doi:10.1001/jamainternmed.2013.2720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/23440284/pubmed" id="23440284" target="_blank">23440284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28110911">
<a name="28110911"></a>Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. <i>Lancet Diabetes Endocrinol</i>. 2017;5(4):251-260. doi:10.1016/S2213-8587(17)30013-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/28110911/pubmed" id="28110911" target="_blank">28110911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Steveling.2014">
<a name="Steveling.2014"></a>Steveling EH, Winzeler B, Bircher AJ. Systemic allergic reaction to the GLP-1 receptor agonist exenatide. <i>Journal of Pharmacy Technology. </i>2014;30(5):182-186. doi:10.1177/8755122514539462</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25375397">
<a name="25375397"></a>Sun F, Chai S, Yu K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. <i>Diabetes Technol Ther</i>. 2015;17(1):35-42. doi:10.1089/dia.2014.0188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/25375397/pubmed" id="25375397" target="_blank">25375397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25633664">
<a name="25633664"></a>Thomsen RW, Pedersen L, Møller N, Kahlert J, Beck-Nielsen H, Sørensen HT. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. <i>Diabetes Care</i>. 2015;38(6):1089-1098. doi:10.2337/dc13-2983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/25633664/pubmed" id="25633664" target="_blank">25633664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29178519">
<a name="29178519"></a>Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes Obes Metab</i>. 2018;20(4):889-897. doi:10.1111/dom.13172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/29178519/pubmed" id="29178519" target="_blank">29178519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36322838">
<a name="36322838"></a>Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. <i>N Engl J Med</i>. 2022;387(24):2245-2257. doi:10.1056/NEJMoa2208601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/36322838/pubmed" id="36322838" target="_blank">36322838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wegovy.2">
<a name="Wegovy.2"></a>Wegovy (semaglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.2022">
<a name="Wexler.2022"></a>Wexler DJ. Initial management of hyperglycemia in adults with type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23622135">
<a name="23622135"></a>Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. <i>Gastroenterology</i>. 2013;144(6):1252-1261. doi:10.1053/j.gastro.2013.01.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/semaglutide-drug-information/abstract-text/23622135/pubmed" id="23622135" target="_blank">23622135</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 115980 Version 224.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
